Physician profile
Joy Bartholomew
NPI 1265498208
$4,302.22
in general payments reported to CMS, 2019-2025
25 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $288 · 2022: $1,817 · 2023: $335 · 2024: $579 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.50 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $516.37 | 2022 | |
| Abbvie INC. | $483.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $463.51 | 2022-2025 | Lynparza, Onglyza |
| Incyte Corporation | $266.09 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Glaxosmithkline, LLC. | $237.88 | 2022-2025 | |
| Genzyme Corporation | $215.40 | 2022-2025 | |
| Beigene USA, INC. | $203.41 | 2023-2024 | Brukinsa |
| Y-Mabs Therapeutics, INC. | $176.89 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $173.22 | 2021-2025 | |
| Syndax Pharmaceuticals, INC. | $160.21 | 2025 | |
| Sobi, INC | $157.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | Opdivo |
| Biohaven Pharmaceutical Holding Company LTD. | $124.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.77 | 2023 | |
| Daiichi Sankyo INC. | $114.64 | 2022-2024 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $112.63 | 2022 | |
| Urovant Sciences INC | $112.30 | 2022 | |
| Merck Sharp & Dohme LLC | $109.98 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pfizer INC. | $98.91 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.88 | 2023-2025 | Fruzaqla, Iclusig, Alunbrig |
| Genmab U.S., INC. | $78.28 | 2023 | Epkinly |
| Emd Serono, INC. | $77.81 | 2024-2025 | |
| Janssen Biotech, INC. | $35.43 | 2025 | Darzalex, Tecvayli |
| United Therapeutics Corporation | $25.28 | 2022 | |
| Tersera Therapeutics LLC | $21.98 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Bartholomew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.